Janssen Biotech (J&J) has agreed a global licence and development deal for Genmab's daratumumab (HuMax(r)-CD38), a human CD38 monoclonal antibody, which is in clinical testing for multiple myeloma. Genmab will receive $55 million up front under the agreement, and J&J will invest DKK475 million (around $80 million) in Genmab, making it the Danish biotech company's largest shareholder.
Janssen Biotech (J&J) has agreed a global licence and development deal for Genmab's daratumumab (HuMax(r)-CD38), a human CD38 monoclonal antibody, which is in clinical testing for multiple myeloma. Genmab will receive $55 million up front under the agreement, and J&J will invest DKK475 million (around $80 million) in Genmab, making it the Danish biotech company's largest shareholder.
J&J is to buy 5.4 million new shares of Genmab at DKK88 per share. Genmab's closing share price on 29...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
